1Tassopoulos NC;Volpes R;Pastore G.Efficacy of lamivudine in patients with hepatitis B e antigen-negative hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B[J],1999(29).
2Jardi R;Buti M;Rodriguez FF;Cotrina M,Costa X,Pascual C,Esteban R,Guardia J.Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants[J],1999(1-2).
3Stuyver l;Van Geyt V;De Gendt S.Line probe for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy,2000.
4Allen MI;Deslauriers M;Andrews CW.Identification and characterization of mutations in hepatitis B virus resistant to lamivudine[J],1998(6).
5Gauthier J;Bourne EJ;Lutz MN.Quantitative assessment of HBV viremia and emergence of YMDD variants in chronic hepatitis B patients treated with lamivudine,1999.
6Lai CL;Chien RN;Leung NW.A one-year trial of lamivudine for chronic hepatitis B[J],1998.
7Leung NW;Lai CL;Chang TT.Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates:results after 3 years of therapy[J],2001.
8Allen M;Gauthier J;Deslauriers M.Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine[J],1999.
9Cane PA;Cook P;Ratcliffe D.Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus[J],1999.
